An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study.
Takuro MizukamiTempei MiyajiYukiya NaritaTomohiro MatsushimaTakashi OguraHiromichi MiyagakiRyohei KawabataYoshiki HorieTakashi KawaguchiKei MuroHiroki HaraTakuhiro YamaguchiTakako Eguchi NakajimaPublished in: Future oncology (London, England) (2021)
Limited data are available regarding the efficacy of nutrition support in advanced gastric cancer (AGC) patients receiving a standard second-line combination chemotherapy. The BALAST study is conducted as a prospective, multicenter observational study to evaluate the efficacy of nutrition support for patients with AGC treated with ramucirumab plus taxane as second-line treatment. As part of the routine care, patients who are malnourished or at risk of malnutrition will receive nutrition support from dietitians. We will enroll a total of 26 patients to estimate weight control rate at 12 weeks as primary end point. This study will generate valuable data reinforcing the role of nutrition support therapy for AGC patients receiving second-line chemotherapy.
Keyphrases
- physical activity
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- palliative care
- electronic health record
- clinical trial
- prognostic factors
- big data
- squamous cell carcinoma
- machine learning
- peritoneal dialysis
- patient reported outcomes
- weight loss
- chronic pain
- weight gain
- quality improvement
- chemotherapy induced